On Mar.21, 2022, CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of investment of ~100 million RMB from Jifeng Ventures, Kunlun Capital, Yinxinggu Capital and Efung Capital.

CellOrigin is committed to develop engineered iPSC-derived CAR-macrophage and CAR-NK cell product. Integrating single cell atlas of differentiation, AI and synthetic biology approaches, CellOrigin developed its technology platform to learn from developmental biology in order to optimize more efficient differentiation methods, and to design more effective cell products. CellOrigin has a strong belief in the advantages and promise brought by iPSC + synthetic biology for the next generation of cell therapy product.

Cellorigin Closed A New Round Of Investment To Jump-Start Its Ipsc Immune Cell Therapy Products Toward Clinics

Cellorigin Closed A New Round Of Investment To Jump-Start Its Ipsc Immune Cell Therapy Products Toward Clinics

Company Info